2018Mini-Reviews in Medicinal ChemistryRequires access

Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging

Jingjing Zhu, Xiaoqing Song, Junbo Zhang

Open publisher page 8 citations

Abstract

Amino acids (AAs) are important nutrients for proliferating tumor cells, and amino acid transport is generally increased in many malignant tumor cells. So far, as a complementary category to 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG), radiolabeled amino acids that target the upregulated level of amino acid transport have been successfully employed for tumor imaging for decades, thanks to their better differentiation between tumor lesions and inflammation. This review summarizes the development of various radiolabeled amino acid analogues for tumor imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) and introduces the basic data related to this area, such as the biological basis, chemical structure, radiolabeling, preclinical evaluation and clinical application. In addition, current status and future prospects of this class of imaging agents are discussed in this review.

About this research paper

What this paper is about

Amino acids (AAs) are important nutrients for proliferating tumor cells, and amino acid transport is generally increased in many malignant tumor cells. So far, as a complementary category to 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG), radiolabeled amino acids that target the upregulated level of amino acid transport have been successfully employed for tumor imaging for decades, thanks to their better differentiation between tumor lesions and inflammation. This review summarizes the development of various radiolabeled amino acid analogues for tumor imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) and introduces the basic data related to this area, such as the biological basis, chemical structure, radiolabeling, preclinical evaluation and clinical application. In addition, current status and future prospects of this class of imaging agents are discussed in this review.

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Amino acids (AAs) are important nutrients for proliferating tumor cells, and amino acid transport is generally increased in many malignant tumor cells. So far, as a complementary category to 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG), radiolabeled amino acids that target the upregulated level of amino acid transport have been successfully employed for tumor imaging for decades, thanks to their better differentiation between tumor lesions and inflammation. This review summarizes the development of various radiolabeled amino acid analogues for tumor imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) and introduces the basic data related to this area, such as the biological basis, chemical structure, radiolabeling, preclinical evaluation and clinical application. In addition, current status and future prospects of this class of imaging agents are discussed in this review.

Key concepts: Amino acid, Positron emission tomography, Emission computed tomography, Spect imaging, Cancer research, Chemistry, Tumor cells, Amino acid transporter

Related papers

Back to paper searchBrowse research topicsOriginal source
Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging — Research Paper | ScholarLens